Theravance Biopharma (TBPH) Raised to “Hold” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a sell rating to a hold rating in a research report report published on Wednesday, May 30th.

A number of other brokerages also recently issued reports on TBPH. ValuEngine downgraded Theravance Biopharma from a hold rating to a sell rating in a report on Wednesday, March 7th. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a buy rating in a report on Tuesday, February 27th. Leerink Swann boosted their price target on Theravance Biopharma from $45.00 to $48.00 and gave the company an outperform rating in a report on Thursday, February 8th. Needham & Company LLC reissued a buy rating and issued a $40.00 price target on shares of Theravance Biopharma in a report on Wednesday, May 9th. Finally, Zacks Investment Research downgraded Theravance Biopharma from a hold rating to a sell rating in a report on Tuesday, May 1st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Theravance Biopharma currently has a consensus rating of Hold and an average target price of $39.29.

Shares of Theravance Biopharma traded down $0.18, reaching $23.83, on Wednesday, MarketBeat Ratings reports. 140,300 shares of the stock were exchanged, compared to its average volume of 237,781. The company has a quick ratio of 4.08, a current ratio of 4.25 and a debt-to-equity ratio of 3.53. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $43.44. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -4.37 and a beta of 1.80.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.04. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. The firm had revenue of $8.32 million during the quarter, compared to the consensus estimate of $5.74 million. research analysts anticipate that Theravance Biopharma will post -4.8 EPS for the current fiscal year.

In other news, EVP Bradford J. Shafer sold 14,040 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $23.97, for a total value of $336,538.80. Following the completion of the sale, the executive vice president now directly owns 133,324 shares in the company, valued at $3,195,776.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Bradford J. Shafer sold 10,140 shares of the business’s stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $24.09, for a total value of $244,272.60. Following the sale, the executive vice president now owns 133,324 shares of the company’s stock, valued at $3,211,775.16. The disclosure for this sale can be found here. Insiders sold 34,180 shares of company stock valued at $823,711 over the last 90 days. Company insiders own 6.90% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG increased its position in shares of Theravance Biopharma by 88.4% during the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 2,117 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Theravance Biopharma during the first quarter worth approximately $130,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Theravance Biopharma during the first quarter worth approximately $202,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $313,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $416,000. Hedge funds and other institutional investors own 85.62% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply